Skip to content

Effect of intravenous Dexamethasone on pain free duration after nerve block for upper limb surgeries in adults

Effect of intravenous Dexamethasone on the duration of analgesia provided by Supraclavicular Brachial Plexus block for upper limb surgeries in adults

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/031910
Enrollment
75
Registered
2021-03-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M968- Other intraoperative and postprocedural complications and disorders of musculoskeletal system, not elsewhere classified

Interventions

Intervention1: Dexamethasone: 4 mg IV dexamethasone in 5 ml Normal saline Intervention2: Dexamethasone: 8mg IV dexamethasone in 5 ml normal saline Control Intervention1: Normal Saline: 5ml normal sali

Sponsors

Department of Anaesthesia
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA grade I and II Patients undergoing elective unilateral upper limb surgeries BMI Upto 30 kg/m2 Duration of surgery Upto 180 minutes

Exclusion criteria

Exclusion criteria: Allergic to local anaesthetic Coagulopathy/bleeding disorder Infection at the site of block Pregnancy Pre-existing neurological deficit or neuropathy involving surgical limb

Design outcomes

Primary

MeasureTime frame
Duration of analgesiaTimepoint: Hourly for 6 hours 2 hourly Upto 12 hours at 24 hours

Secondary

MeasureTime frame
- Onset of sensory blockade - Onset of motor blockade - Duration of motor blockade - Cumulative postoperative analgesic requirements in first 24 hours after surgeryTimepoint: Hourly for 6 hours 2 hourly Upto 12 hours at 24 hours

Countries

India

Contacts

Public ContactDr Praveen R S

ABVIMS and Dr.RML Hospital

rsindhoo@yahoo.co.in9717932744

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026